Orabrush products

now in Walgreens

Orabrush, a Provo-based health care products company, said Walgreens is carrying its patented tongue cleaner and its tongue foam in approximately 5,000 stores nationwide. The deal brings the number of retail outlets carrying Orabrush products to nearly 30,000 worldwide.

BSD, cancer center

make another deal

BSD Medical Corp., a Salt Lake City company that sells systems to treat cancer using heat therapy, said Cancer Treatment Centers of America has purchased another BSD-500 Hyperthermia system for its new Southeastern Regional Medical Center in Atlanta. The sale marked the seventh BSD system purchased by CTCA.

Microsoft's Greek

office bombed

Assailants attacked Microsoft's office in Athens, driving a van through the front door and setting off an incendiary device that burned the building's entrance. There were no injuries reported in the pre-dawn attack. There was no immediate claim of responsibility.

T-Mobile's CEO

abruptly resigns

T-Mobile USA, the country's fourth-largest cellphone carrier, said its CEO resigned and its chief operating officer is filling in while the company searches for a replacement. Departing CEO Philipp Humm took the reins in November 2010 with a mission to reverse the slow slide of the business, but revenue continued to decline.

Contracts to buy

U.S. homes rise

Americans signed more contracts to buy previously occupied homes in May, matching the fastest pace in two years. The increase suggests consumers are gaining confidence in the housing market. The National Association of Realtors said its index of sales agreements increased to 101.1 last month. A reading of 100 is considered healthy.

Monsanto 3Q

profit soars

A mild winter spurred farmers to sow crops earlier and in larger numbers, allowing seed company Monsanto Co. to reap a 35 percent higher profit in its third quarter. The company earned $937 million, or $1.74 per share, in the quarter ended in May, compared with $692 million, or $1.28 per share, a year earlier. Revenue rose 17 percent, to $4.22 billion.

Facebook shares

get mixed reviews

The Wall Street analysts who know Facebook best are giving the company's stock a mixed review. A flood of reports from 33 banks gave Facebook's stock a mix of "Neutral" and "Buy" ratings. There was at least one review that equated to a "Sell" rating. Facebook's shares closed Wednesday at $32.23.